MiNK Therapeutics (NASDAQ:INKT) Trading Down 4.2% – What’s Next?

MiNK Therapeutics, Inc. (NASDAQ:INKT)’s share price was down 4.2% during trading on Monday . The company traded as low as $13.35 and last traded at $13.45. Approximately 24,835 shares were traded during trading, a decline of 7% from the average daily volume of 26,630 shares. The stock had previously closed at $14.04.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on INKT shares. B. Riley raised MiNK Therapeutics to a “strong-buy” rating in a research report on Friday, July 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. HC Wainwright raised MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Friday, August 15th. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 20th. Finally, Wall Street Zen cut MiNK Therapeutics to a “strong sell” rating in a research note on Saturday, August 23rd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

MiNK Therapeutics Price Performance

The firm has a 50 day moving average of $14.55 and a two-hundred day moving average of $12.52. The stock has a market cap of $60.79 million, a PE ratio of -4.67 and a beta of 0.33.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51). As a group, equities analysts anticipate that MiNK Therapeutics, Inc. will post -2.75 EPS for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.